Spotlight
Money Desk
Obituaries
Classifieds
Families First
News
Weather
Specialists
Sports
Business
Opinion
Consumer
Health
Life
Out & About
Login
Weather
45 NC counties and 1 VA county are under alert, including Wake, Cumberland, Durham, Johnston, and Orange counties.
Breaking News
Former Wake County Sheriff responsible for retaliating against two former deputies, jury says
Just In
Salary released: New UNC chancellor will make less than predecessor. Here's what Lee Roberts will be paid.
Program
On WRAL at 6: Hundreds of millions overbudget, WRAL Investigates delays in a Medicaid upgrade costing taxpayers and impacting patients
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Dow Jones Industrial Average
Nasdaq Composite
Standard & Poors 500
Gold
Crude Oil
Local Stocks
WRALTechWire 30
WRALTechWire 30
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Veracyte, Inc.
< Previous
1
2
3
4
Next >
Veracyte to Participate in Upcoming Investor Conferences
February 27, 2023
From
Veracyte, Inc.
Via
Business Wire
Tickers
VCYT
Veracyte Announces Fourth Quarter and Full-Year 2022 Financial Results
February 22, 2023
From
Veracyte, Inc.
Via
Business Wire
Tickers
VCYT
Data Published in “The Red Journal” Validate Prognostic Value of Veracyte’s Decipher Prostate Genomic Classifier for Men with High-Risk Prostate Cancer
February 15, 2023
From
Veracyte, Inc.
Via
Business Wire
Tickers
VCYT
New Data To Be Presented at 2023 ASCO GU Suggest Decipher GRID-Derived Gene Expression Signature Can Help Personalize Prostate Cancer Treatment
February 13, 2023
From
Veracyte, Inc.
Via
Business Wire
Tickers
VCYT
Veracyte to Release Fourth Quarter and Full-Year 2022 Financial Results on February 22, 2023
February 06, 2023
From
Veracyte, Inc.
Via
Business Wire
Tickers
VCYT
Veracyte Announces Multiple Decipher Urologic Testing Abstracts to be Presented at the 2023 ASCO Genitourinary (GU) Cancers Symposium
February 01, 2023
From
Veracyte, Inc.
Via
Business Wire
Tickers
VCYT
Veracyte Announces New Data Suggesting Afirma Testing Can Help Personalize Care for Patients with Thyroid Nodules
February 01, 2023
From
Veracyte, Inc.
Via
Business Wire
Tickers
VCYT
Data Published in JCEM Demonstrate Strong Real-World Performance of Veracyte’s Afirma GSC in Thyroid Cancer Diagnosis
December 15, 2022
From
Veracyte, Inc.
Via
Business Wire
Tickers
VCYT
Veracyte Announces Third Quarter 2022 Financial Results
November 02, 2022
From
Veracyte, Inc.
Via
Business Wire
Tickers
VCYT
Veracyte Announces Three Abstracts to Be Presented at SITC 2022 Annual Meeting
November 01, 2022
From
Veracyte, Inc.
Via
Business Wire
Tickers
VCYT
Veracyte to Participate in the Credit Suisse 31st Annual Healthcare Conference
October 27, 2022
From
Veracyte, Inc.
Via
Business Wire
Tickers
VCYT
New Data Suggest Decipher GRID-Derived Genomic Signature Can Help Identify Men with Prostate Cancer Who Should Receive High-Dose Radiotherapy
October 25, 2022
From
Veracyte, Inc.
Via
Business Wire
Tickers
VCYT
Veracyte Data Presented at ATA Annual Meeting Provide New Insights into Molecular Underpinnings of Thyroid Cancer
October 24, 2022
From
Veracyte, Inc.
Via
Business Wire
Tickers
VCYT
New Data Presented at CHEST 2022 Reinforce Clinical Value of Veracyte’s Genomic Tests in Interstitial Lung Disease and Lung Cancer
October 18, 2022
From
Veracyte, Inc.
Via
Business Wire
Tickers
VCYT
Veracyte to Release Third Quarter 2022 Financial Results on November 2, 2022
October 13, 2022
From
Veracyte, Inc.
Via
Business Wire
Tickers
VCYT
New Data Published in JNCI Demonstrate Veracyte’s Decipher Prostate Genomic Classifier May Improve Identification of Aggressive Prostate Cancer in African American Men
September 22, 2022
From
Veracyte, Inc.
Via
Business Wire
Tickers
VCYT
Veracyte Names John Leite, Ph.D., as General Manager of Pulmonology & Market Access
September 13, 2022
From
Veracyte, Inc.
Via
Business Wire
Tickers
VCYT
New Data Presented at ESMO 2022 Show Veracyte’s Decipher Prostate Genomic Classifier May Help Inform Personalized Treatment Decisions in Men with Advanced Prostate Cancer
September 11, 2022
From
Veracyte, Inc.
Via
Business Wire
Tickers
VCYT
New Data Suggest Veracyte’s Envisia Genomic Classifier Can Help Predict Disease Progression in Interstitial Lung Disease Patients Treated with Combination Immunosuppressive Therapy
September 07, 2022
From
Veracyte, Inc.
Via
Business Wire
Tickers
VCYT
Veracyte to Participate in the Morgan Stanley 20th Annual Global Healthcare Conference
September 01, 2022
From
Veracyte, Inc.
Via
Business Wire
Tickers
VCYT
Veracyte Announces Seven Abstracts to Be Presented at ESMO Congress 2022
August 31, 2022
From
Veracyte, Inc.
Via
Business Wire
Tickers
VCYT
New Data in Nature Medicine Suggest Pre-Treatment Tumor Microenvironment Can Impact Response for CAR T-Cell Therapy in Patients with Large B-Cell Lymphoma
August 29, 2022
From
Veracyte, Inc.
Via
Business Wire
Tickers
VCYT
Veracyte Appoints Eliav Barr, M.D., to Its Board of Directors
August 11, 2022
From
Veracyte, Inc.
Via
Business Wire
Tickers
VCYT
Veracyte Announces Second Quarter 2022 Financial Results
August 02, 2022
From
Veracyte, Inc.
Via
Business Wire
Tickers
VCYT
Veracyte Announces New Clinical Validation Data for RNA Sequencing-Based Afirma Medullary Thyroid Cancer Classifier Published in Thyroid
July 20, 2022
From
Veracyte, Inc.
Via
Business Wire
Tickers
VCYT
Veracyte to Release Second Quarter 2022 Financial Results on August 2, 2022
July 14, 2022
From
Veracyte, Inc.
Via
Business Wire
Tickers
VCYT
New Data Published in PLOS ONE Validate the Clinical Performance of Veracyte’s Percepta Genomic Sequencing Classifier in Lung Cancer Diagnosis
July 13, 2022
From
Veracyte, Inc.
Via
Business Wire
Tickers
VCYT
Veracyte Named a San Francisco “Bay Area Top Workplace” For Ninth Consecutive Year
June 27, 2022
From
Veracyte, Inc.
Via
Business Wire
Tickers
VCYT
New Data Show Strong Performance of Veracyte’s Afirma GSC in Real-World Clinical Practice
June 20, 2022
From
Veracyte, Inc.
Via
Business Wire
Tickers
VCYT
Data Published in Annals of Oncology Reinforce Clinical Utility of Veracyte’s Decipher Prostate Genomic Classifier for Informing Treatment of Men Experiencing Prostate Cancer Progression
June 03, 2022
From
Veracyte, Inc.
Via
Business Wire
Tickers
VCYT
< Previous
1
2
3
4
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.